$13.47
1.68% yesterday
Nasdaq, Dec 04, 10:00 pm CET
ISIN
US89532M1018
Symbol
TRVI

Trevi Therapeutics, Inc. Stock price

$13.47
+2.61 24.03% 1M
+6.89 104.71% 6M
+9.35 226.94% YTD
+10.87 418.08% 1Y
+11.38 544.50% 3Y
+10.42 341.64% 5Y
+5.58 70.72% 10Y
+5.58 70.72% 20Y
Nasdaq, Closing price Thu, Dec 04 2025
-0.23 1.68%
ISIN
US89532M1018
Symbol
TRVI
Industry

Key metrics

Basic
Market capitalization
$1.8b
Enterprise Value
$1.6b
Net debt
positive
Cash
$203.9m
Shares outstanding
121.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.9
Financial Health
Equity Ratio
89.9%
Return on Equity
-48.1%
ROCE
-25.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-51.3m | $-58.0m
EBIT
$-51.4m | $-56.6m
Net Income
$-47.1m | $-48.6m
Free Cash Flow
$-42.8m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-19.7% | -12.9%
EBIT
-19.7% | -9.9%
Net Income
-22.2% | -1.3%
Free Cash Flow
-31.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
13.3%
Employees
26
Rev per Employee
$0.0
Show more

Is Trevi Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Trevi Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Trevi Therapeutics, Inc. forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Trevi Therapeutics, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Trevi Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 14 14
20% 20%
-
- Research and Development Expense 38 38
19% 19%
-
-51 -51
20% 20%
-
- Depreciation and Amortization 0.15 0.15
7% 7%
-
EBIT (Operating Income) EBIT -51 -51
20% 20%
-
Net Profit -47 -47
22% 22%
-

In millions USD.

Don't miss a Thing! We will send you all news about Trevi Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Trevi Therapeutics, Inc. Stock News

Neutral
PRNewsWire
about 11 hours ago
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn. , Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non...
Positive
Seeking Alpha
one day ago
Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically significant efficacy in phase 2b CORAL study [IPF] and phase 2a RIVER [RCC], with a differentiated dual central/peripheral mechanism of action. The company is well-capitalized, with $194.9M in cas...
Neutral
Seeking Alpha
21 days ago
Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - S...
More Trevi Therapeutics, Inc. News

Company Profile

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.

Head office United States
CEO Jennifer Good
Employees 26
Founded 2011
Website www.trevitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today